{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T07:58:50Z","timestamp":1790323130835,"version":"4.1.0"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Drug Discov"],"DOI":"10.1038\/s41573-026-01538-9","type":"journal-article","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T07:02:00Z","timestamp":1790319720000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["From N-of-1 therapy to health-system implementation"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8440-3074","authenticated-orcid":false,"given":"Haiyan","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice E.","family":"Davidson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mina","family":"Ryten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ella F.","family":"Whittle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Lench","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"O\u2019Connor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8307-6638","authenticated-orcid":false,"given":"Carlo","family":"Rinaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9102-5232","authenticated-orcid":false,"given":"Francesco","family":"Muntoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,25]]},"reference":[{"key":"1538_CR1","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/s41573-024-01059-3","volume":"24","author":"AH Jonker","year":"2025","unstructured":"Jonker, A. H. et al. The state-of-the-art of N-of-1 therapies and the IRDiRC N-of-1 development roadmap. Nat. Rev. Drug Discov. 24, 40\u201356 (2025).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1538_CR2","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1056\/NEJMoa1813279","volume":"381","author":"J Kim","year":"2019","unstructured":"Kim, J. et al. Patient-customized oligonucleotide therapy for a rare genetic disease. N. Engl. J. Med. 381, 1644\u20131652 (2019).","journal-title":"N. Engl. J. Med."},{"key":"1538_CR3","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1016\/S0140-6736(25)00513-6","volume":"405","author":"NA Shneider","year":"2025","unstructured":"Shneider, N. A. et al. Antisense oligonucleotide jacifusen for FUS-ALS: an investigator-initiated, multicentre, open-label case series. Lancet 405, 2075\u20132086 (2025).","journal-title":"Lancet"},{"key":"1538_CR4","doi-asserted-by":"publisher","first-page":"gkaf346","DOI":"10.1093\/nar\/gkaf346","volume":"53","author":"J Belgrad","year":"2025","unstructured":"Belgrad, J. et al. The N=1 Collaborative: advancing customized nucleic acid therapies through collaboration and data sharing. Nucleic Acids Res. 53, gkaf346 (2025).","journal-title":"Nucleic Acids Res."},{"key":"1538_CR5","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1056\/NEJMoa2504747","volume":"392","author":"K Musunuru","year":"2025","unstructured":"Musunuru, K. et al. Patient-specific in vivo gene editing to treat a rare genetic disease. N. Engl. J. Med. 392, 2235\u20132243 (2025).","journal-title":"N. Engl. J. Med."},{"key":"1538_CR6","doi-asserted-by":"publisher","first-page":"gkag504","DOI":"10.1093\/nar\/gkag504","volume":"54","author":"ST Crooke","year":"2026","unstructured":"Crooke, S. T. et al. Addressing the needs of nano-rare patients: the n-Lorem experience. Nucleic Acids Res. 54, gkag504 (2026).","journal-title":"Nucleic Acids Res."},{"key":"1538_CR7","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/j.ajhg.2025.02.017","volume":"112","author":"D Cheerie","year":"2025","unstructured":"Cheerie, D. et al. Consensus guid elines for assessing eligibility of pathogenic DNA variants for antisense oligonucleotide treatments. Am. J. Hum. Genet. 112, 975\u2013983 (2025).","journal-title":"Am. J. Hum. Genet."},{"key":"1538_CR8","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1001\/jamaneurol.2026.1021","volume":"83","author":"E Sherrill","year":"2026","unstructured":"Sherrill, E. et al. Precision antisense oligonucleotide therapy amenability for infantile genetic epilepsies. JAMA Neurol. 83, 598\u2013601 (2026).","journal-title":"JAMA Neurol."},{"key":"1538_CR9","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1038\/s41591-025-03547-4","volume":"31","author":"DJ O\u2019Connor","year":"2025","unstructured":"O\u2019Connor, D. J. et al. The Rare Therapies Launchpad: a pilot program for individualized medicines in the UK. Nat. Med. 31, 1379\u20131380 (2025).","journal-title":"Nat. Med."},{"key":"1538_CR10","doi-asserted-by":"publisher","unstructured":"Whittle, E. F. et al. A scalable and equitable framework for target and patient prioritisation in rare disease antisense therapeutics. Preprint at medRxiv https:\/\/doi.org\/10.64898\/2026.03.23.26348690 (2026).","DOI":"10.64898\/2026.03.23.26348690"}],"container-title":["Nature Reviews Drug Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41573-026-01538-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41573-026-01538-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41573-026-01538-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T07:02:01Z","timestamp":1790319721000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41573-026-01538-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,25]]},"references-count":10,"alternative-id":["1538"],"URL":"https:\/\/doi.org\/10.1038\/s41573-026-01538-9","relation":{},"ISSN":["1474-1776","1474-1784"],"issn-type":[{"value":"1474-1776","type":"print"},{"value":"1474-1784","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,25]]},"assertion":[{"value":"25 September 2026","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}